Weight loss drugs currently cost anywhere from $149 to over $1,000 per month, depending on the specific medication, how you get it, and whether you have insurance. That range is shifting fast. Recent government deals and new pill formulations are pushing prices down, but for many people, these medications still represent a significant monthly expense.
List Prices Without Insurance
The brand-name injectable medications that dominate the market, Wegovy and Zepbound, carry retail prices between $500 and $1,000 per month without any discount or coverage. Ozempic, which is approved for diabetes but widely prescribed off-label for weight loss, lists at $900 to $1,100 per month. These are the sticker prices you’d face walking into a pharmacy with no insurance and no savings card.
Almost nobody should pay those full prices anymore. Both Novo Nordisk (maker of Wegovy) and Eli Lilly (maker of Zepbound) now offer significantly reduced cash-pay options. Wegovy’s newer pill form starts at $149 per month for lower doses, rising to $299 per month for the highest doses. The Wegovy pen starts at $199 per month for the first two months on introductory doses, then jumps to $349 per month for maintenance doses. Zepbound’s lowest dose is available for $299 per month, with higher doses priced at $449 per month for cash-paying patients.
What You’ll Pay With Insurance
If you have commercial insurance that covers weight loss medications, manufacturer savings cards can drop your copay dramatically. Wegovy’s savings program advertises a price as low as $25 per month for eligible patients with commercial coverage. The catch is that your insurer has to cover the drug in the first place, and many still don’t, or they impose strict requirements before approving it.
To qualify for insurance coverage, you typically need a BMI of 30 or higher, or a BMI of 27 or higher combined with a weight-related health condition like high blood pressure, high cholesterol, type 2 diabetes, sleep apnea, or heart disease. Even when you meet those criteria, most insurers require prior authorization, meaning your doctor has to submit paperwork justifying the prescription before the pharmacy will fill it. Some plans also require step therapy, where you must try and fail other treatments first.
Medicare and Medicaid Coverage
Medicare currently cannot cover weight loss drugs by law. It does cover GLP-1 medications when prescribed for type 2 diabetes, cardiovascular disease, or sleep apnea. So if you’re on Medicare and have one of those conditions, you may be able to get coverage for the same drug through a different diagnosis. The FDA approved Wegovy for cardiovascular risk reduction and Zepbound for sleep apnea in 2024, which opened the door for some Medicare patients.
A new government model called BALANCE aims to change this. Starting in 2026 for Medicaid and 2027 for Medicare, participating plans will be able to cover GLP-1 medications for obesity. Under a deal struck with the drug manufacturers, prices to Medicare and Medicaid would fall to $245 per month, with Medicare copays capped at $50 per month. This program is voluntary for drug companies, states, and insurance plans, so coverage will vary by location.
Medicaid coverage right now is spotty. As of early 2023, only about 1 in 5 state Medicaid programs covered any anti-obesity medication. Most states did cover GLP-1 drugs for diabetes, but if your primary diagnosis is obesity, the majority of state Medicaid programs won’t pay for them yet.
Telehealth Programs and Total Costs
Telehealth platforms like Ro, Hims, and others offer bundled weight loss programs that include a medical consultation and ongoing provider support. These memberships add a layer of cost on top of the medication itself. Ro, for example, charges $45 for the first month and $145 per month after that for its membership. Medication is billed separately, starting at $149 per month for lower doses of Wegovy’s pill.
That means the real monthly total through a telehealth platform can range from roughly $300 to $600 when you combine the membership fee with the medication cost. The advantage is convenience and built-in medical oversight. The downside is that these fees add up. Over a year, you could spend $3,600 to $7,200 depending on the dose and platform.
The Long-Term Price Tag
Weight loss drugs are not a short-term treatment for most people. Research consistently shows that weight returns when the medication stops, which means many patients face an open-ended commitment. At $149 per month on the low end, that’s roughly $1,800 per year. At $449 per month for a higher dose of Zepbound, it’s nearly $5,400 per year. Those figures don’t include medical visits, lab work, or the telehealth membership fees some providers charge.
There are also indirect costs to consider. A Yale analysis found that non-medication healthcare expenses increased by about $80 per month during the second year of treatment, adding roughly $1,000 annually. This likely reflects the additional monitoring and follow-up care that comes with long-term medication use.
Upcoming Price Drops
Prices are trending downward. A government initiative is creating a direct-to-consumer site where the average price for injectable and pill GLP-1 medications will start at or below $350 per month, with an expectation to fall to $245 within two years. Both major manufacturers have committed to these price reductions for cash-paying customers, with the changes taking effect no later than January for cash payers and by mid-2026 for Medicare patients.
Eli Lilly is also developing an oral weight loss pill called orforglipron, expected to receive approval in early 2026. The starter dose would cost $149 per month through government pricing channels, with higher doses capped at $399 per month for repeat purchasers. A pill option could reduce costs further by eliminating the manufacturing complexity of injectable devices.
Even with these reductions, a $350 monthly price point remains out of reach for many households. The medication alone would cost $4,200 per year, a significant expense that most budgets can’t absorb indefinitely without insurance support.